Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Viridian Therapeutics, Inc.\DE reported revenue of $71M, up 23359.9% year over year. Operating margin was -512.9% and net margin -483.6%, on a free-cash-flow margin of -390.8% with capital expenditure at 0.7% of revenue. Every figure is computed directly from VRDN's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $71M | -512.9% | -483.6% |
| FY2024 | $0M | -99018.2% | -89387.1% |
| FY2023 | $0M | -81035.0% | -75711.5% |
| FY2022 | $2M | -7579.2% | -7329.2% |
| FY2021 | $3M | -2690.8% | -2680.2% |
How does VRDN compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.